Verilumia 
AstraZeneca agrees to invest $2 billion in Summit
AstraZeneca has agreed to invest $2 billion in Summit Therapeutics through a purchase of convertible preferred shares, alongside a planned cancer-drug research collaboration centered on Summit’s investigational treatm...
